ZIVO Bioscience, Inc. (ZIVO)
- Previous Close
8.00 - Open
7.30 - Bid --
- Ask --
- Day's Range
8.00 - 8.00 - 52 Week Range
0.48 - 19.08 - Volume
39 - Avg. Volume
2,517 - Market Cap (intraday)
22.221M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-4.60 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
www.zivobioscience.comRecent News: ZIVO
Performance Overview: ZIVO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIVO
Valuation Measures
Market Cap
22.22M
Enterprise Value
22.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
488.97
Price/Book (mrq)
--
Enterprise Value/Revenue
806.26
Enterprise Value/EBITDA
-3.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-338.92%
Return on Equity (ttm)
--
Revenue (ttm)
27.65k
Net Income Avi to Common (ttm)
-7.78M
Diluted EPS (ttm)
-4.60
Balance Sheet and Cash Flow
Total Cash (mrq)
274.38k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.86M